BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Neuren Pharmaceuticals Limited Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs


8/10/2012 9:51:31 AM

SYDNEY, AUSTRALIA--(Marketwire - August 10, 2012) - Neuren Pharmaceuticals Limited (ASX: NEU) is pleased to announce that Dr Joseph Horrigan has joined the company as Vice President of Clinical Development and Medical Affairs. Dr Horrigan most recently served as Assistant Vice President and Head of Medical Research at Autism Speaks, North America's largest autism science and advocacy organization. In that role, he oversaw the organization's medical research and training programs including consulting with academic and industry groups on clinical trial design and endpoints in neurodevelopmental disorders. He is a widely respected neuropsychiatrist and has been a practicing child and adolescent psychiatrist since 1992.

From 2002 until he joined Autism Speaks, Dr Horrigan coordinated paediatric drug development in the Neurosciences Medicines Development Center at GlaxoSmithKline. He also directed GlaxoSmithKline's Medicines for Children Advisory Network, which consults with all therapeutic areas on paediatric drug development issues. He has led Phase 1 through 4 clinical development programs across a wide range of neurologic and psychiatric conditions including bipolar disorder, attention-deficit/hyperactivity disorder (ADHD), multiple sclerosis, Alzheimer's disease, schizophrenia, major depressive disorder, insomnia, paediatric epilepsy, and neurodevelopmental disorders. In addition, Dr Horrigan is a Clinical Associate Professor in the Department of Psychiatry at the University of North Carolina at Chapel Hill.

Commenting on Dr Horrigan's appointment, Larry Glass, Neuren's CEO, said: "We are delighted to have Joe join the company. His expertise and insight will contribute immensely to our clinical development programs. As we advance the clinical trials in neurodevelopmental disorders and head injury, Joe's leadership and perspective will be critical to study design and execution in these important and challenging indications which clearly depend on creative and ethical research to be successful."

Dr Horrigan added, "Neuren is uniquely situated to make a significant contribution to the delivery of better therapeutics for several rare and common CNS conditions that have a growing public health impact. In addition, Neuren has emerged as a thoughtful and adept clinical development organization with a sophisticated understanding of unmet medical needs and an appreciation for the importance of always placing the patient first. It is a real pleasure to join this team."

About Neuren
Neuren Pharmaceuticals is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders and cancer. Neuren presently has two clinical-stage molecules, NNZ-2566 and Motiva®, in Phase 2 clinical trials largely funded by the US Army and the National Health and Medical Research Council, respectively. Through its subsidiary, Perseis Therapeutics Limited, Neuren is developing monoclonal antibodies against Trefoil Factors 1 and 3, proteins produced by cancer cells that are associated with cancer spread and reduced patient survival.


For more information, please contact:
Larry Glass
Neuren CEO
lglass@neurenpharma.com
Tel: +1 301 941 1830



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES